For instance, for Epstein-Barr virus, the researchers targeted EBNA1, a constitutively expressed gene in EBV-infected cells, and this, they reported, led to a 50 percent to 60 percent decline of latent EBV in their experimental cell line. When they added a second gRNA aimed at a separate part of EBNA1, they observed a 95 percent loss of EBV.
https://www.genomeweb.com/scan/crispr-strategy-herpesviruses
https://www.genomeweb.com/scan/crispr-strategy-herpesviruses